BofA moved to No Rating from Underperform on Sage Therapeutics (SAGE) after the company announced a definitive agreement to be acquired by Supernus Pharmaceuticals (SUPN) for a total up to $12 per share. Sage shares are no longer trading on fundamentals given the deal announcement, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics downgraded to Neutral from Overweight at Piper Sandler
- Sarepta suspends Elevidys shipments, Supernus acquires Sage: Morning Buzz
- Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus
- Video: Sarepta, Hinge Health among major pre-market movers
- SAGE Therapeutics Announces Merger with Supernus Pharmaceuticals